A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
An increase in the total red cell mass of the blood. (Dorland, 27th ed)
A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Increased numbers of platelets in the peripheral blood. (Dorland, 27th ed)
Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
An antineoplastic agent that acts by alkylation.
The cells in the erythroid series derived from MYELOID PROGENITOR CELLS or from the bi-potential MEGAKARYOCYTE-ERYTHROID PROGENITOR CELLS which eventually give rise to mature RED BLOOD CELLS. The erythroid progenitor cells develop in two phases: erythroid burst-forming units (BFU-E) followed by erythroid colony-forming units (CFU-E); BFU-E differentiate into CFU-E on stimulation by ERYTHROPOIETIN, and then further differentiate into ERYTHROBLASTS when stimulated by other factors.
The techniques used to draw blood from a vein for diagnostic purposes or for treatment of certain blood disorders such as erythrocytosis, hemochromatosis, polycythemia vera, and porphyria cutanea tarda.
The production of red blood cells (ERYTHROCYTES). In humans, erythrocytes are produced by the YOLK SAC in the first trimester; by the liver in the second trimester; by the BONE MARROW in the third trimester and after birth. In normal individuals, the erythrocyte count in the peripheral blood remains relatively constant implying a balance between the rate of erythrocyte production and rate of destruction.
Cell surface proteins that bind erythropoietin with high affinity and trigger intracellular changes influencing the behavior of cells.
The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value.
Cell surface receptors that are specific for THROMBOPOIETIN. They signal through interaction with JANUS KINASES such as JANUS KINASE 2.
Puncture of a vein to draw blood for therapeutic purposes. Bloodletting therapy has been used in Talmudic and Indian medicine since the medieval time, and was still practiced widely in the 18th and 19th centuries. Its modern counterpart is PHLEBOTOMY.
A ubiquitin-protein ligase that mediates OXYGEN-dependent polyubiquitination of HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT. It is inactivated in VON HIPPEL-LINDAU SYNDROME.
The formation and development of blood cells outside the BONE MARROW, as in the SPLEEN; LIVER; or LYMPH NODES.
Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.
Volume of circulating ERYTHROCYTES . It is usually measured by RADIOISOTOPE DILUTION TECHNIQUE.
A SOMATOSTATIN-secreting tumor derived from the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS). It is also found in the INTESTINE. Somatostatinomas are associated with DIABETES MELLITUS; CHOLELITHIASIS; STEATORRHEA; and HYPOCHLORHYDRIA. The majority of somatostatinomas have the potential for METASTASIS.
An individual in which both alleles at a given locus are identical.
Formation and development of a thrombus or blood clot in the blood vessel.
A subclass of lipid-linked proteins that contain a GLYCOSYLPHOSPHATIDYLINOSITOL LINKAGE which holds them to the CELL MEMBRANE.
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
A mutation in which a codon is mutated to one directing the incorporation of a different amino acid. This substitution may result in an inactive or unstable product. (From A Dictionary of Genetics, King & Stansfield, 5th ed)
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
The naturally occurring or experimentally induced replacement of one or more AMINO ACIDS in a protein with another. If a functionally equivalent amino acid is substituted, the protein may retain wild-type activity. Substitution may also diminish, enhance, or eliminate protein function. Experimentally induced substitution is often used to study enzyme activities and binding site properties.
Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.
A bluish or purplish discoloration of the skin and mucous membranes due to an increase in the amount of deoxygenated hemoglobin in the blood or a structural defect in the hemoglobin molecule.
The series of cells in the red blood cell lineage at various stages of differentiation.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
Very large BONE MARROW CELLS which release mature BLOOD PLATELETS.
A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion, such as the carotid body, or medulla of the adrenal gland (usually called a chromaffinoma or pheochromocytoma). It is more common in women than in men. (Stedman, 25th ed; from Segen, Dictionary of Modern Medicine, 1992)
ERYTHROCYTE size and HEMOGLOBIN content or concentration, usually derived from ERYTHROCYTE COUNT; BLOOD hemoglobin concentration; and HEMATOCRIT. The indices include the mean corpuscular volume (MCV), the mean corpuscular hemoglobin (MCH), and the mean corpuscular hemoglobin concentration (MCHC).
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
A transient increase in the number of leukocytes in a body fluid.
The number of RED BLOOD CELLS per unit volume in a sample of venous BLOOD.
An individual having different alleles at one or more loci regarding a specific character.
A condition in which the hepatic venous outflow is obstructed anywhere from the small HEPATIC VEINS to the junction of the INFERIOR VENA CAVA and the RIGHT ATRIUM. Usually the blockage is extrahepatic and caused by blood clots (THROMBUS) or fibrous webs. Parenchymal FIBROSIS is uncommon.
The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements.
Progenitor cells from which all blood cells derive.
Multiple symptoms associated with reduced oxygen at high ALTITUDE.
Enlargement of the spleen.
A myelodysplastic/myeloproliferative disorder characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to CHRONIC MYELOID LEUKEMIA, but cytogenetically lacking a PHILADELPHIA CHROMOSOME or bcr/abl fusion gene (GENES, ABL).
The short, metacentric human chromosomes, called group F in the human chromosome classification. This group consists of chromosome pairs 19 and 20.
A humoral factor that stimulates the production of thrombocytes (BLOOD PLATELETS). Thrombopoietin stimulates the proliferation of bone marrow MEGAKARYOCYTES and their release of blood platelets. The process is called THROMBOPOIESIS.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.

Insulin-like growth factor I plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis. (1/419)

Erythroid progenitor growth, the serum hormones that regulate erythropoiesis, and the effect of patient's serum on the growth of normal erythroid progenitors were assessed in eight patients with end-stage renal disease (ESRD) and erythrocytosis. All patients were male and had been on maintenance dialysis, they had a hematocrit >50% and/or a red blood cell count >6 x 10(12)/L and an arterial oxygen saturation >95%. Four had acquired cystic disease of the kidney (ACDK), and four other non-ACDK patients did not have known causes of secondary erythrocytosis after appropriate investigations and long-term follow-up. The methylcellulose culture technique was used to assay the erythroid progenitor (BFU-E/CFU-E) growth. Serum erythropoietin (EPO) and insulin-like growth factor I (IGF-I) levels were measured by RIA. Paired experiments were performed to determine the effects of 10% sera from ESRD patients and control subjects on normal marrow CFU-E growth. The numbers of EPO-dependent BFU-E in marrow and/or blood of patients with ESRD and erythrocytosis were higher than those of normal controls. No EPO-independent erythroid colonies were found. Serum EPO levels were constantly normal in one patient and elevated in three patients with ACDK; for non-ACDK patients, EPO levels were normal or low in two patients and persistently increased in one, but fluctuated in the remaining one on serial assays. There was no correlation between serum EPO levels and hematocrit values. The serum IGF-I levels in patients with ESRD and erythrocytosis were significantly increased compared with normal subjects or ESRD patients with anemia. We found an inverse correlation between serum EPO and IGF-I levels. Sera from patients with ESRD and erythrocytosis exhibited a stimulating effect on normal marrow CFU-E growth. The stimulating effect of sera from patients who had a normal serum EPO level and an elevated IGF-I level could be partially blocked by anti-IGF-I. The present study suggests that IGF-I plays an important role in the regulation of erythropoiesis in patients with ESRD and erythrocytosis who did not have an increased EPO production.  (+info)

Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. (2/419)

Prostacyclin synthase (PGIS) is the final committed enzyme in the metabolic pathway leading to prostacyclin (PGI2) production. Patients with severe pulmonary hypertension have a PGIS deficiency of their precapillary vessels, but the importance of this deficiency for lung vascular remodeling remains unclear. We hypothesized that selective pulmonary overexpression of PGIS may prevent the development of pulmonary hypertension. To study this hypothesis, transgenic mice were created with selective pulmonary PGIS overexpression using a construct of the 3.7-kb human surfactant protein-C (SP-C) promoter and the rat PGIS cDNA. Transgenic mice (Tg+) and nontransgenic littermates (Tg-) were subjected to a simulated altitude of 17,000 ft for 5 weeks, and right ventricular systolic pressure (RVSP) was measured. Histology was performed on the lungs. The Tg+ mice produced 2-fold more pulmonary 6-keto prostaglandin F1alpha (PGF1alpha) levels than did Tg- mice. After exposure to chronic hypobaric hypoxia, Tg+ mice have lower RVSP than do Tg- mice. Histologic examination of the lungs revealed nearly normal arteriolar vessels in the Tg+ mice in comparison with vessel wall hypertrophy in the Tg- mice. These studies demonstrate that Tg+ mice were protected from the development of pulmonary hypertension after exposure to chronic hypobaric hypoxia. We conclude that PGIS plays a major role in modifying the pulmonary vascular response to chronic hypoxia. This has important implications for the pathogenesis and treatment of severe pulmonary hypertension.  (+info)

Localization of the gene responsible for familial benign polycythemia to chromosome 11q23. (3/419)

Familial benign polycythemia (FBP) (OMIM 263400) is a rare autosomal recessive condition characterized by erythrocytosis, normal leukocyte and platelet counts, normal uric acid level, and usually increased erythropoietin production. There is a high incidence of this disorder in Chuvashia (Russian Federation), probably due to a founder effect. In an attempt to locate the gene responsible for this disorder, we have carried out linkage studies in 12 Chuvash families, with 35 affected and 32 unaffected members. Linkage to the erythropoietin and erythropoietin receptor loci was excluded, and the FBP gene was assigned to the region of chromosome 11q23 between D11S4142 and D11S1356, with a maximal lod score of 6.61.  (+info)

Activation of the erythropoietin receptor by the gp55-P viral envelope protein is determined by a single amino acid in its transmembrane domain. (4/419)

The spleen focus forming virus (SFFV) gp55-P envelope glycoprotein specifically binds to and activates murine erythropoietin receptors (EpoRs) coexpressed in the same cell, triggering proliferation of erythroid progenitors and inducing erythroleukemia. Here we demonstrate specific interactions between the single transmembrane domains of the two proteins that are essential for receptor activation. The human EpoR is not activated by gp55-P but by mutation of a single amino acid, L238, in its transmembrane sequence to its murine counterpart serine, resulting in its ability to be activated. The converse mutation in the murine EpoR (S238L) abolishes activation by gp55-P. Computational searches of interactions between the membrane-spanning segments of murine EpoR and gp55-P provide a possible explanation: the face of the EpoR transmembrane domain containing S238 is predicted to interact specifically with gp55-P but not gp55-A, a variant which is much less effective in activating the murine EpoR. Mutational studies on gp55-P M390, which is predicted to interact with S238, provide additional support for this model. Mutation of M390 to isoleucine, the corresponding residue in gp55-A, abolishes activation, but the gp55-P M390L mutation is fully functional. gp55-P is thought to activate signaling by the EpoR by inducing receptor oligomerization through interactions involving specific transmembrane residues.  (+info)

Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state. (5/419)

Inherited mutations in the erythropoietin receptor (EPOR) causing premature termination of the receptor cytoplasmic region are associated with dominant familial erythrocytosis (FE), a benign clinical condition characterized by hypersensitivity of erythroid progenitor cells to EPO and low serum EPO (S-EPO) levels. We describe a Swedish family with dominant FE in which erythrocytosis segregates with a new truncation in the negative control domain of the EPOR. We show that cells engineered to concomitantly express the wild-type (WT) EPOR and mutant EPORs associated with FE (FE EPORs) are hypersensitive to EPO-stimulated proliferation and activation of Jak2 and Stat5. These results demonstrate that FE is caused by hyperresponsiveness of receptor-mediated signaling pathways and that this is dominant with respect to WT EPOR signaling.  (+info)

Role of the spleen in the exaggerated polycythemic response to hypoxia in chronic mountain sickness in rats. (6/419)

In a rat model of chronic mountain sickness, the excessive polycythemic response to hypoxic exposure is associated with profound splenic erythropoiesis. We studied the uptake and distribution of radioactive iron and red blood cell (RBC) morphology in intact and splenectomized rats over a 30-day hypoxic exposure. Retention of (59)Fe in the plasma was correlated with (59)Fe uptake by both spleen and marrow and the appearance of (59)Fe-labeled RBCs in the blood. (59)Fe uptake in both the spleen and the marrow paralleled the production of nucleated RBCs. Splenic (59)Fe uptake was approximately 10% of the total marrow uptake under normoxic conditions but increased to 60% of the total marrow uptake during hypoxic exposure. Peak splenic (59)Fe uptake and splenomegaly occurred at the most intense phase of erythropoiesis and coincided with the rapid appearance of (59)Fe-labeled RBCs in the blood. The bone marrow remains the most important erythropoietic organ under both resting and stimulated states, but inordinate splenic erythropoiesis in this rat strain accounts in large measure for the excessive polycythemia during the development of chronic mountain sickness in chronic hypoxia.  (+info)

Neutrophil alkaline phosphatase score in chronic granulocytic leukaemia: effects of splenectomy and antileukaemic drugs. (7/419)

Staining with naphthol AS phosphate and Fast Blue BB salt has been used for the estimation of neutrophil alkaline phosphatase (NAP) scores in patients with chronic granulocytic leukaemia (CGL). The very low scores found at diagnosis rise when the disease is treated, and there is some inverse correlation between the NAP score and the absolute neutrophil count. Patients treated intensively developed high NAP scores. Elective splenectomy performed during the chronic phase of CGL is followed by a pronounced but transient neutrophilia and a concurrent striking rise in the NAP score. Similar changes were observed in patients without CGL who underwent splenectomy. These observations can be explained by assuming that newly formed neutrophils in CGL have a normal content of NAP but are rapidly sequestered in non-circulating extramedullary pools, whereas the circulating neutrophil with a typically low NAP content is a relatively aged cell which has lost enzyme activity. In subjects with or without CGL, removal of the spleen, a major site of such pooling, temporarily permits the circulation of newly formed neutrophils but eventually other organs assume the sequestering functions of the spleen. Thus the aberrations of NAP score seen in CGL might be attributable not to an intrinsic cellular defect but to an exaggeration of the granulocyte storage phenomena which also occur in subjects without CGL.  (+info)

Significance of an abnormally low or high hemoglobin concentration during pregnancy: special consideration of iron nutrition. (8/419)

An association between moderate anemia and poor perinatal outcomes has been found through epidemiologic studies, although available evidence cannot establish this relation as causal. Anemia may not be a direct cause of poor pregnancy outcomes, except in the case of maternal mortality resulting directly from severe anemia due to hypoxia and heart failure. Preventing or treating anemia, whether moderate or severe, is desirable. Because iron deficiency is a common cause of maternal anemia, iron supplementation is a common practice to reduce the incidence of maternal anemia. Nevertheless, the effectiveness of large-scale supplementation programs needs to be improved operationally and, where multiple micronutrient deficiencies are common, supplementation beyond iron and folate can be considered. High hemoglobin concentrations are often mistaken as adequate iron status; however, high hemoglobin is independent of iron status and is often associated with poor health outcomes. Very high hemoglobin concentrations cause high blood viscosity, which results in both compromised oxygen delivery to tissues and cerebrovascular complications. Epidemiologic studies have also found an association between high maternal hemoglobin concentrations and an increased risk of poor pregnancy outcomes. Evidence does not suggest that this association is causal; it could be better attributed to hypertensive disorders of pregnancy and to preeclampsia. The pathophysiologic mechanism of these conditions during pregnancy can produce higher hemoglobin concentrations because of reduced normal plasma expansion and cause fetal stress because of reduced placental-fetal perfusion. Accordingly, higher than normal hemoglobin concentrations should be regarded as an indicator of possible pregnancy complications, not necessarily as a sign of adequate iron nutrition, because iron supplementation does not increase hemoglobin higher than the optimal concentration needed for oxygen delivery.  (+info)

Synonyms: Familial erythrocytosis, Primary congenital erythrocytosis, Familial erythrocytosis type 1, ECYT1, Polycythemia, primary familial and congenital, PFCP, Erythrocytosis autosomal dominant benign, Congenital polycythemia due to erythropoietin receptor mutation, Congenital erythrocytosis due to erythropoietin receptor mutation, Autosomal dominant familial erythrocytosis-1, Familial erythrocytosis 1, Primary familial polycythemia ...
Genetic Heterogeneity of Familial Erythrocytosis See also ECYT2 ({263400}), caused by mutation in the VHL gene ({608537}) on chromosome 3p25; ECYT3 ({609820}), caused by mutation in the EGLN1 gene ({606425}) on chromosome 1q42; and ECYT4 ({611783}), caused by mutation in the EPAS1 gene ({603349}) on chromosome 2p. Erythrocytosis may also be caused by somatic mutation in the JAK2 ({147796}) or the SH2B3 ({605093}) gene on chromosome 9p24 and 12q24, respectively. For a review of the genetics of congenital erythrocytosis, see {3:Bento et al. (2014 ...
JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera.: A single mutation 1849G|T in the JAK2 gene (V617F) has recently
OBJECTIVE: Myeloproliferative neoplasms (MPNs) like essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) are acquired clonal hematopoietic stem cell disorders and originate from a multipotent hematopoietic stem cell. The SOCS1 and SOCS3 genes are negative regulators of the JAK/STAT signal pathway. In this study we investigate the promoter methylation of these genes in the pathogenesis of MPNs and secondary erythrocytosis/thrombocythemia ...
Erythrocytosis generally develops in those renal transplant recipients who have good renal function and without evidence of acute and chronic rejection.1 In our study PTE patients had excellent graft functions, with mean serum creatinine of 1.06±0.29mg/dl at the onset of PTE. At the end of follow up the serum creatinine was 1.00±0.35 mg/dl. Patients with post transplant erythrocytosis in our study had a higher value of acute rejection episodes, which is rather unexpected and contrary to most previous studies showing that PTE occurs in those who had rejection free course before developing erythrocytosis. In 7 out of 13 patients who had acute rejection in PTE group, episode of acute rejection occurred well after development of erythrocytosis suggesting that acute rejection episode was non contributing to erythrocytosis. In remaining 6 patients acute rejection preceded PTE. In all these later patients rejection occurred in early transplant period with good reversal. Their renal functions were ...
The continuing debate concerning the use of ionizing radiation and especially radiophosphorus (32P) for the treatment of the patient with polycythemia vera and the relationship of such treatment to the overall survival of this group of patients forms the background and provides the raison dêtre for this excellent monograph. The writing is clear and has an authoritative ring. The scholarship is thorough; the references include more than 850 cited articles.. The monograph is divided into four sections: a review of erythropoiesis, polycythemia vera, secondary polycythemia, and other polycythemic entities. Appropriately the bulk of the monograph relates to polycythemia vera, with ...
Erythrapheresis was performed in 10 patients with polycythaemia secondary to hypoxic lung disease (mean PaO2, 6.8 kPa (51 mm Hg)). The mean packed cell volume decreased from 0.64 to 0.48 in men and from 0.56 to 0.42 in women, with significant decreases in blood viscosity at both high and low shear rates (p less than 0.001). Patients showed significant improvement in six-minute walking distances (p less than 0.001) and in tests of mental alertness (p less than 0.01) compared to control subjects. Visual analogue scales confirmed symptomatic improvement after erythrapheresis. Erythrapheresis significantly improved symptoms, mental function, and work performance in patients with polycythaemia secondary to hypoxic lung disease. The procedure was well tolerated by all patients and no complications occurred. ...
PubMedID: 26177275 | Fetal and neonatal iron deficiency but not copper deficiency increases vascular complexity in the developing rat brain. | Nutritional neuroscience | 11/1/2015
We have generated a transgenic mouse line that reaches a hematocrit concentration of 0.85 due to constitutive overexpression of human erythropoietin in an oxygen-independent manner. Unexpectedly, this excessive erythrocytosis did not lead to thrombembolic complications in all investigated organs at any age. Thus, we investigated the mechanisms preventing thrombembolism in this mouse model. Blood analysis revealed an age-dependent elevation of reticulocyte numbers and a marked thrombocytopenia that matched the reduced megakaryocyte numbers in the bone marrow. However, platelet counts were not different from wild-type controls, when calculations were based on the distribution (eg, plasma) volume, thereby explaining why thrombopoietin levels did not increase in transgenic mice. Nevertheless, bleeding time was significantly increased in transgenic animals. A longitudinal investigation using computerized thromboelastography revealed that thrombus formation was reduced with increasing age from 1 to 8 ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Polycytemia is commonly associated with COPD but recent reports suggest that anaemia is also prevalentAim:The aim of this study was to determine the prevelance of anaemia in patients with COPD who referred to PR programme and to explore the clinical and functional associations between anaemia.. Materials and Methods:398 COPD patients who referred to Atatürk Chest Disease and Chest Surgery Traning Hospital PR Center between January 2008 December 2011 were evaluated retrospectively and 176 patients were included.. Patients were classified as anaemic,polycythemic or normal.Dyspnea was assessed with the MRC and CRQ dyspnea scale;quality of life was assessed with SGRQ.Exercise capacity was measured using the ISWT,ESWT,body composition was assessed with BMI,FFMI,anxiety and depression were assessed with the HADS.. Results:Anaemia was present in 14(8%)patients and polycythemia in 24(14%).BMI,FFM,FFMI,MRC,endurance time (ET)differed between anaemic,normal and polycythemic patients though there were no ...
In conclusion, the concept of the erythron is discussed as a logical way to approach the physiology of erythropoiesis and as a basis for understanding the pathophysiological disturbances whIch characterise the red cell abnormalities. Using this approach, both increase in red cell mass, or erythrocytosis, and decrease in red cell mass, or anaemia, are seen simply as manifestations of a disturbance in the normal regulatory mechanisms of the erythron.
Cobalt increases the red cell mass in both man and animals by increasing the production of erythropoietin. Since meat-type chickens can develop pulmonary hypertension from increased erythropoiesis and polycythaemia, two trials were conducted to inves
Background: Secondary Polycythemia (SP) mean an elevated of erythrocytes numbers and hemoglobin above normal levels which as more than 18 g / liter in males or 16 g / liter in females, and the elevated red blood cell above the normal level lead to many complication as thromboembolisim, hypertension, and gout.Objectives: The study aims to assess find out the effectiveness of instructional program application on secondary polycythemic clients. Methodology: A quasi-experimental design study conducted in Iraqi national blood bank from the period of January, 13th 2015 to September, 1st 2015, the study sample consist of 70 clients have hemoglobin level more than 18 mg/dl for males and 16 mg/dl for females, divided into two groups (35) case and (35) control groups.The study instrument was composed of three parts which as socio- demographic information was included; (age group, gender, marital status, level of education and occupational, and second parts deals medical history which include (weight, ...
A case of hepatoma associated with erythrocytosis and increased levels of plasma ESF is described. Normal or tumorous liver tissue from this patient possessed neither erythropoiesis-stimulating activity nor a capacity to generate the ESF when incubated with normal human serum. Homogenates of tumor tissue served effectively as substrate for hypoxic rat REF in the generation of the ESF. Homogenates of nontumorous liver exhibited no substrate activity, but inactivated human urinary ESF when incubated with it. Homogenates of tumorous liver tissue lacked the capacity to inactivate the ESF.. It is suggested that the increased production or availability of substrate for the REF by the tumor significantly contributed to the increased levels of plasma ESF in this patient. ...
Background: High altitude renal syndrome has been described in populations with excessive erythrocytosis. We evaluated whether high altitude (HA) dwellers might be at increased risk for kidney disease. Methods: We performed a cross-sectional study to investigate differences in prevalence of kidney function and metabolic syndrome in healthy subjects living at HA vs. sea level (SL) without any known history of hypertension, diabetes or chronic kidney disease. Results: We examined 293 subjects, aged 40 to 60 years: 125 SL (154 m) and 168 HA (3640 m) dwellers. HA dwellers had higher serum creatinine, lower estimated glomerular function rate (eGFR) (69.5 ± 15.2 vs. 102.1 ± 17.8 ml/min/1.73 m2, p , 0.0001), more proteinuria and higher hemoglobin concentrations compared to SL subjects. HA subjects had a lower prevalence of metabolic syndrome. Hemoglobin concentrations correlated inversely with eGFR in female (p = 0.001) and male (p = 0.03) HA dwellers. Using logistic regression analysis to compare ...
Erythrocytosis is an increase in circulating red blood cells. With timely identification & appropriate treatment, patients can lead high quality lives.
Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people. ...
Cario H, Schwarz K, Jorch N, et al. Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica. 2005;90(1):19-24.
Estimated risk of hospital death: *If the patient has a history of severe organ system insufficiency or is immunocompromised as defined below, assign points as follows: 5 points for nonoperative or emergency postoperative patients 2 points for elective postoperative patients Definitions: Organ insufficiency or immunocompromised state must have been evident prior to this hospital admission and conform to the following criteria: Liver--biopsy proven cirrhosis and documented portal hypertension; episodes of past upper GI bleeding attributed to portal hypertension; or prior episodes of hepatic failure/encephalopathy/coma. Cardiovascular--New York Heart Association Class IV. Respiratory--Chronic restrictive, obstructive, or vascular disease resulting in severe exercise restriction (i.e., unable to climb stairs or perform household duties; or documented chronic hypoxia, hypercapnia, secondary polycythemia, severe pulmonary hypertension (>40 mmHg), or respirator dependency. Renal--receiving chronic ...
Estimated risk of hospital death: *If the patient has a history of severe organ system insufficiency or is immunocompromised as defined below, assign points as follows: 5 points for nonoperative or emergency postoperative patients 2 points for elective postoperative patients Definitions: Organ insufficiency or immunocompromised state must have been evident prior to this hospital admission and conform to the following criteria: Liver--biopsy proven cirrhosis and documented portal hypertension; episodes of past upper GI bleeding attributed to portal hypertension; or prior episodes of hepatic failure/encephalopathy/coma. Cardiovascular--New York Heart Association Class IV. Respiratory--Chronic restrictive, obstructive, or vascular disease resulting in severe exercise restriction (i.e., unable to climb stairs or perform household duties; or documented chronic hypoxia, hypercapnia, secondary polycythemia, severe pulmonary hypertension (>40 mmHg), or respirator dependency. Renal--receiving chronic ...
The discussion will emphasize ways to identify non-PAH patients with chronic heart failure, normal wedge pressures, and hypoxic lung disease, specifically discussing hemodynamic clues and whether
Cancer Therapy Advisor provides hematology professionals with the latest hematology conditions, procedures and guides for different surgical and non surgical conditions. Visit often for updates and new information.
Looking for online definition of polycythaemia in the Medical Dictionary? polycythaemia explanation free. What is polycythaemia? Meaning of polycythaemia medical term. What does polycythaemia mean?
Report Highlights. A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Polycythemia Vera. In the coming years, the Polycythemia Vera market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies and academics that are working to assess challenges and seek opportunities that could influence Polycythemia Vera R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.. A detailed portfolio of major pharma players who are involved in fueling the Polycythemia Vera treatment market. Several potential therapies for Polycythemia Vera are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Polycythemia Vera market size in the coming years. ...
Primary polycythemias are due to factors intrinsic to red cell precursors. Polycythemia vera (PCV), polycythemia rubra vera (PRV), or erythremia, occurs when excess red blood cells are produced as a result of an abnormality of the bone marrow.[3] Often, excess white blood cells and platelets are also produced. PCV is classified as a myeloproliferative disease. Symptoms include headaches and vertigo, and signs on physical examination include an abnormally enlarged spleen and/or liver. In some cases, affected individuals may have associated conditions including high blood pressure or formation of blood clots. Transformation to acute leukemia is rare. Phlebotomy is the mainstay of treatment. A hallmark of polycythemia is an elevated hematocrit, with Hct , 55% seen in 83% of cases.[4] A somatic (non-hereditary) mutation (V617F) in the JAK2 gene is found in 95% of cases, though also present in other myeloproliferative disorders.[5]. Primary familial polycythemia, also known as primary familial and ...
Primary polycythemias are due to factors intrinsic to red cell precursors. Polycythemia vera (PCV), polycythemia rubra vera (PRV), or erythremia, occurs when excess red blood cells are produced as a result of an abnormality of the bone marrow.[3] Often, excess white blood cells and platelets are also produced. PCV is classified as a myeloproliferative disease. Symptoms include headaches and vertigo, and signs on physical examination include an abnormally enlarged spleen and/or liver. In some cases, affected individuals may have associated conditions including high blood pressure or formation of blood clots. Transformation to acute leukemia is rare. Phlebotomy is the mainstay of treatment. A hallmark of polycythemia is an elevated hematocrit, with Hct , 55% seen in 83% of cases.[4] A somatic (non-hereditary) mutation (V617F) in the JAK2 gene is found in 95% of cases, though also present in other myeloproliferative disorders.[5] Primary familial polycythemia, also known as primary familial and ...
Polycythaemia Rubra Vera (PRV) is known as polycythaemia vera, plethora vera, primary polycythaemia, Osler-Vaquez disease. Polycythaemia rubra vera (PRV) common form.
TY - JOUR. T1 - Polycythemia vera. T2 - A case report and discussion on pathogenic mechanisms of increased thrombosis. AU - Gumina, Richard J.. AU - Foley, David A.. AU - Tefferi, Ayalew. AU - Rooke, Thom W.. AU - Shields, Raymond C.. PY - 2002. Y1 - 2002. N2 - Polycythemia vera is a myeloproliferative disorder characterized by increased red cell mass and frequently complicated by venous and arterial thrombosis. The mechanism underlying the increased incidence of thrombotic events remains illusive. Presented in this report are a case of a 77-year-old man diagnosed with polycythemia vera and a review of the current literature on the mechanisms underlying the increased incidence of thrombotic events in polycythemia vera.. AB - Polycythemia vera is a myeloproliferative disorder characterized by increased red cell mass and frequently complicated by venous and arterial thrombosis. The mechanism underlying the increased incidence of thrombotic events remains illusive. Presented in this report are a ...
A. A male patient with JAK2 V617F mutation, hemoglobin of 13.5 g/dL, and subnormal serum erythropoietin level. B. A male patient with JAK2 V617F mutation, hemoglobin of 16.5 g/dL, and subnormal serum erythropoietin level. C. A patient with JAK2 V617F mutation, hemoglobin of 18.5 g/dL, and subnormal serum erythropoietin level. D. A and B are correct. Question 2 Which of the following is a minor criterion to facilitate the diagnosis of polycythemia vera?. A. Elevated hematocrit of , 48% in women and , 49% in men. B. Elevated hemoglobin of , 16.0 g/dL in women and , 16.5 g/dL in men. C. Bone marrow biopsy showing age-adjusted hypercellularity with panmyelosis and pleomorphic mature megakaryocytes. D. Subnormal serum erythropoietin level. Question 3 Which of the following is a well-described bone marrow characteristic of polycythemia vera?. A. Unilineage erythroid hyperplasia. B. Age-adjusted hypercellularity. C. Pleomorphic immature megakaryocytes. D. All of the above. Question 4 Which of the ...
A. A male patient with JAK2 V617F mutation, hemoglobin of 13.5 g/dL, and subnormal serum erythropoietin level. B. A male patient with JAK2 V617F mutation, hemoglobin of 16.5 g/dL, and subnormal serum erythropoietin level. C. A patient with JAK2 V617F mutation, hemoglobin of 18.5 g/dL, and subnormal serum erythropoietin level. D. A and B are correct. Question 2 Which of the following is a minor criterion to facilitate the diagnosis of polycythemia vera?. A. Elevated hematocrit of , 48% in women and , 49% in men. B. Elevated hemoglobin of , 16.0 g/dL in women and , 16.5 g/dL in men. C. Bone marrow biopsy showing age-adjusted hypercellularity with panmyelosis and pleomorphic mature megakaryocytes. D. Subnormal serum erythropoietin level. Question 3 Which of the following is a well-described bone marrow characteristic of polycythemia vera?. A. Unilineage erythroid hyperplasia. B. Age-adjusted hypercellularity. C. Pleomorphic immature megakaryocytes. D. All of the above. Question 4 Which of the ...
A relationship between polycythemia and obesity became apparent to us during observation of a massively obese patient who had serious renal, hepatic and cardiorespiratory disturbances, as well as marked polycythemia. Polycythemia and the other disturbances were remarkably reversed in this patient by dietary weight reduction without any other therapy.1, 2 Baez Villaseñor and his co-workers3 had previously described a 5% incidence of polycythemia in a group of 240 obese patients studied in Mexico. Incidental reference to the presence of obesity in cases of atypical erythremia and the observation of unusual plethora in obese individuals were made by several other authors.4-6 ...
Lay Summary: Polycythemia vera is a chronic blood cancer that can cause severe complications and early death. Differences in clinical features and outcome have been observed in younger (age ≤ 45) versus older (age ≥ 65) patients with PV. We seek to understand the basis for these differences, and propose a series of genetic and functional studies to address these issues. The long term goal of this work is to leverage the findings from this study to improve longevity for patients with PV.. Full Summary: Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) that is defined by erythrocytosis and associated with thrombotic complications and a propensity for transformation to myelofibrosis (MF) or secondary acute myeloid leukemia (sAML). Overall survival for patients with PV is substantially impaired compared to age-matched controls. Recent studies have identified age-related differences in disease characteristics and clinical outcome in PV, including distinct JAK2 V617F allele ...
Polycythaemia vera (PV) is an MPN characterized by excessive proliferation of erythrocyte, thrombocyte and granulocyte cell lines, but the clinical symptoms are related to the erythrocytosis. We say that the proliferation is trilinear, as it involves the three cell lines of the myeloid cell line.. The erythrocytosis causes haemoglobin and haematocrit levels to be elevated compared to normal. There is mild neutrophilia and basophilia. The erythrocytosis causes the blood to become more viscous. Hyperviscocity increases the risk for thrombosis and vascular stasis. The increased RBC count causes splenomegaly. The serum level of EPO is low and can be used to differentiate PV from other causes of polycythaemia.. Mutations of JAK2, which is usually bound to the EPO receptor, causes haematopoietic stem cells to be independent of EPO for proliferation.. The prognosis of PV is very good.. ...
Basel, June 13, 2015 - Novartis today announced long-term safety and efficacy results from the pivotal Phase III RESPONSE study evaluating Jakavi® (ruxolitinib) for the treatment of patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. A preplanned analysis of the study at 18 months demonstrated that 80% of patients with inadequately controlled PV treated with Jakavi experienced a durable response of sustaining hematocrit less than 45% without the use of phlebotomy and reducing spleen size, two key measures of disease control, for at least one year[1]. Findings were presented at the 20th Congress of the European Hematology Association (EHA) in Vienna, Austria.. Polycythemia vera can lead to serious complications if inadequately controlled, and these data demonstrate the ability of Jakavi to provide a durable and comprehensive clinical benefit in this patient population, said lead study investigator Jean-Jacques Kiladjian, MD, PhD, Hôpital Saint-Louis et ...
Polycythemia vera is one type of myeloproliferative disorder (MPD). Bone marrow contains stem cells that have the ability to mature into adult blood cells that enter the circulation, including red blood cells, white blood cells, and platelets. These stem cells are referred to as pluripotent hematopoeitic precursor cells, or PHPC, due to their versatility. Each PHPC can reproduce itself (clone), in addition to producing daughter cells, called blasts.. In MPD, one abnormal PHPC clone has an ability to overgrow and self-renew more effectively then normal PHPC clones. In polycythemia vera, there may be an increase in just the red blood cells, both the red and white blood cells, or in the red and white blood cells and platelets.. The abnormal PHPC clone is the result of mutations to genes in these cells. These mutations are not inherited, but happen during a persons lifetime. Why this happens to a given individual is unknown in most cases.. ...
CancerConnect News: A new drug called Jakafi® (ruxolitinib) appears to help patients with polycythemia vera (PV) maintain hematocrit control more effectively than best available therapy. These findings were presented at the 56th American Hematology Society Annual Meeting and Exposition, December 6-9, 2014, in San Francisco, California.[1]. Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. In PV the bone marrow makes too many blood cells, particularly red blood cells. These excess cells thicken the blood and can cause complications, such as a risk of blood clots or bleeding. Without treatment, PV can be life threatening and can eventually progress to more serious blood cancers, such as myelofibrosis or acute leukemia. Effective treatment, however, can significantly decrease risks and complications.. The ...
A Phase III trial finds that Jakafi® (ruxolitinib) is more effective than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine.. Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. In PV the bone marrow makes too many blood cells, particularly red blood cells. These excess cells thicken the blood and can cause complications, such as a risk of blood clots or bleeding. Without treatment, PV can be life threatening and can eventually progress to more serious blood cancers, such as myelofibrosis or acute leukemia. Effective treatment, however, can significantly decrease risks and complications.. The goal of therapy for PV is to reduce the thickness of the blood and prevent bleeding and clotting. Jakafi has proven effective in the therapy ...
CancerConnect News: A Phase III trial finds that Jakafi® (ruxolitinib) is more effective than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine.. Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. In PV the bone marrow makes too many blood cells, particularly red blood cells. These excess cells thicken the blood and can cause complications, such as a risk of blood clots or bleeding. Without treatment, PV can be life threatening and can eventually progress to more serious blood cancers, such as myelofibrosis or acute leukemia. Effective treatment, however, can significantly decrease risks and complications.. The goal of therapy for PV is to reduce the thickness of the blood and prevent bleeding and clotting. Jakafi has proven ...
Polycythemia vera is a serious, but very rare blood disorder in children. With polycythemia vera, the bone marrow makes too many red blood cells. The extra cells make the blood too thick. This may lead to blood clots. The clots can decrease the blood supply to organs, tissues, and cells.
There are no CT scan findings associated with polycythemia vera. However, a CT scan may be helpful in the diagnosis of complications of polycythemia vera, which include:[1][2] ...
Polycythemia is a laboratory finding in which there is an increased number of red blood cells (RBC), along with an accompanying increase in the concentration of hemoglobin in the peripheral blood. The approach to the patient with polycythemia will be
Mild polycythemia may not cause problems. However, too many red blood cells can increase the blood volume or thicken the blood, making it harder to circulate through the blood system and to the organs. Babies can have difficulty breathing and their heart and blood vessels cannot compensate for the extra amount of blood. As the large numbers of cells begin to break down, a substance called bilirubin is produced. Increased bilirubin levels, called hyperbilirubinemia, can cause jaundice, a yellowing of the skin, eyes, and mucous membranes. Seizures can also occur with polycythemia.. ...
Mild polycythemia may not cause problems. However, too many red blood cells can increase the blood volume or thicken the blood, making it harder to circulate through the blood system and to the organs. Babies can have difficulty breathing and their heart and blood vessels cannot compensate for the extra amount of blood. As the large numbers of cells begin to break down, a substance called bilirubin is produced. Increased bilirubin levels, called hyperbilirubinemia, can cause jaundice, a yellowing of the skin, eyes, and mucous membranes. Seizures can also occur with polycythemia. ...
List of 11 disease causes of Polycythemia in pregnancy, patient stories, diagnostic guides. Diagnostic checklist, medical tests, doctor questions, and related signs or symptoms for Polycythemia in pregnancy.
Erythrocytosis Overview A high red blood cell count indicates there are too many red blood cells circulating in your bloodstream. Red blood cells (RBCs), a
Schuler, B; Rieger, G; Gubser, M; Arras, M; Gianella, M; Vogel, O; Jirkof, P; Cesarovic, N; Klohs, J; Jakob, P; Brock, M; Gorr, T A; Baum, O; Hoppeler, H; Samillan-Soto, V; Gassmann, M; Fischer, J A; Born, W; Vogel, J (2014). Endogenous α-calcitonin-gene-related peptide promotes exercise-induced, physiological heart hypertrophy in mice. Acta Physiologica, 211(1):107-121.. Hlushchuk, R; Ehrbar, M; Reichmuth, P; Heinimann, N; Styp-Rekowska, B; Escher, R; Baum, O; Lienemann, P; Makanya, A; Keshet, E; Djonov, V (2011). Decrease in VEGF expression induces intussusceptive vascular pruning. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(12):2836-2844.. Richter, V; Savery, M D; Gassmann, M; Baum, O; Damiano, E; Pries, A R (2011). Excessive erythrocytosis compromises the blood-endothelium interface in erythropoietin-overexpressing mice. Journal of Physiology, 589(21):5181-5192.. Picard, N; Baum, O; Vogetseder, A; Kaissling, B; Le Hir, M (2008). Origin of renal myofibroblasts in the model of ...
Chronic exposure to high altitude is associated with the development of erythrocytosis, proteinuria, and, in some cases, hyperuricemia. We examined the relationship between high-altitude polycythemia and proteinuria and hyperuricemia in Cerro de Pasc
In this case-based interview, Ruben A. Mesa, MD, discusses the case of a young male patient with polycythemia vera not adequately controlled on phlebotomy and hydroxyurea.
In this case-based interview, Ruben A. Mesa, MD, discusses the case of a young male patient with polycythemia vera not adequately controlled on phlebotomy and hydroxyurea.
Polycythemia vera is a rare blood disorder that occurs more often in men than in women. Its rarely seen in anyone under age 40. PV is usually associated with a gene mutation called JAK2 V617F. The JAK2 gene handles production of a protein that helps make blood cells. About 95 percent of people with PV have this mutation.. Mutations are changes or damage in the bodys DNA. DNA is responsible for all of your physical characteristics, from eye color to fingerprints. The mutation that causes PV can be acquired, which means something has damaged the DNA (instead of being born with it) and passed on within families. More research needs to be done to understand what causes the genetic mutation behind PV.. If you have PV, the genetic mutation causes your bone marrow to produce too many red blood cells. The production of red blood cells within your bone marrow is normally tightly regulated. Having too many red blood cells in your bloodstream can cause the blood to clot and lead to dangerous ...
Of 113 Patients with polycythemia vera (P. vera) who had been followed for the last 8 years, 30 cases (27%) developed myeloid leukemia with fibrosis of the bone marrow. Core biopsies of the bone...
Could moving to a warm, lower altitude place help polycythemia vera? I now live at 4,750ft. above sea level, cold dry climate. My doctor says no, it wont help the...
Polycythemia vera (PV) develops when the body makes too many red blood cells and sometimes too many white blood cells or platelets. Learn about PV.
Polycythemia vera is a condition where genetic mutation results in too many red blood cells. Treatment options are focused on preventing blood clots.
Phyllis George, former sportscaster and Miss America, dies at 70 from complications related to polycythemia vera (PV), an uncommon blood cancer.
Stem cell transplantation for polycythemia vera. - Harald Reinhard, Thomas Klingebiel, Peter Lang, Peter Bader, Dietrich Niethammer, Norbert Graf
[66 Pages Report] Check for Discount on Polycythemia Vera - Pipeline Review, H2 2017 report by Global Markets Direct. Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline...
Rawlings et al developed a nomogram for estimating blood volume in a neonate with polycythemia. The blood volume per kilogram body weight varies with the body weight. The authors are from Tripler Army Medical Center in Honolulu.
My 37 years old husband is suffering from hypertension. He is taking Telmisartan for the last six months and now his blood pressure ranges at 120/80 mm/ Hg. His hemoglobin was 18.2 g/dl for the last 10 years but now came down to 16.9 g/dl. His hematocrit value has also come down and is presently 49. His blood counts are all in the normal range. His TIBC, serum Vitamin B12 is just a bit below normal. His serum iron is normal and EPO is 7.2. His liver function test came normal. He has no enlargement of the liver or spleen, pain, thrombosis or pruritis. |b|A haematologist suggested that he is suffering from polycythemia and has asked him to get a Janus kinase 2 (JAK 2) test done.|/b| He also had an attack of pseudo gout three months back. Is it normal to have high haemoglobin level?
Learn more about Primary Polycythemia at Doctors Hospital of Augusta DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Learn more about Primary Polycythemia at LewisGale Regional Health System DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL R200W mutation (Chuvash polycythemia). Haematologica, Vol.97, No.2 (2012): 193-200. Sable, C.A., Zakari Y. Aliyu, Dham, N., Mehdi Nouraie, Sachdev, V., Sidenko, S., Miasnikova, G.Y., Polyakova, L.A., Sergueeva, A.I., Okhotin, D.J., Bushuev, V., Remaley, A.T., Xiaomei Niu, Oswaldo L. Castro, Gladwin, M.T., Kato, G.J., Prchal, J.T., Victor R. Gordeuk.. ...
Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL R200W mutation (Chuvash polycythemia). Haematologica, Vol.97, No.2 (2012): 193-200. Sable, C.A., Zakari Y. Aliyu, Dham, N., Mehdi Nouraie, Sachdev, V., Sidenko, S., Miasnikova, G.Y., Polyakova, L.A., Sergueeva, A.I., Okhotin, D.J., Bushuev, V., Remaley, A.T., Xiaomei Niu, Oswaldo L. Castro, Gladwin, M.T., Kato, G.J., Prchal, J.T., Victor R. Gordeuk.. ...
Polycythemia vera (PV)[edit]. PV is associated most often with the JAK2 V617F mutation in greater than 95% of cases, whereas ... 2005). "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera". Nature. 434 (7037): 1144- ... 2005). "Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation ... 2005). "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia ...
FST Polycythemia vera; 263300; JAK2 Polycythemia, benign familial; 263400; VHL Polydactyly, postaxial, types A1 and B; 174200; ...
Anemia and polycythemia. in: Braunwald E, et al. Harrison's Principles of Internal Medicine. (15th Edition). McGraw Hill (New ...
Polycythemia can also occur. In children, chronic hypoxemia may manifest as delayed growth, neurological development and motor ...
Causes include polycythemia and hyperfibrinogenemia. Treatment aims to increase the amount of oxygen in the blood and reverse ...
The gold standard for the diagnosis of Vitamin B12 deficiency is a low blood level of Vitamin B12. A low level of blood Vitamin B12 is a finding that normally can and should be treated by injections, supplementation, or dietary or lifestyle advice, but it is not a diagnosis. Hypovitaminosis B12 can result from a number of mechanisms, including those listed above. For determination of cause, further patient history, testing, and empirical therapy may be clinically indicated. A measurement of methylmalonic acid (methylmalonate) can provide an indirect method for partially differentiating Vitamin B12 and folate deficiencies. The level of methylmalonic acid is not elevated in folic acid deficiency. Direct measurement of blood cobalamin remains the gold standard because the test for elevated methylmalonic acid is not specific enough. Vitamin B12 is one necessary prosthetic group to the enzyme methylmalonyl-coenzyme A mutase. Vitamin B12 deficiency is but one among the conditions that can lead to ...
The specific cause is dependent of the type of TMA that is presented, but the two main pathways that lead to TMA are external triggers of vascular injury, such as viruses, bacterial Shiga toxins or endotoxins, antibodies, and drugs; and congenital predisposing conditions, including decreased levels of tissue factors necessary for the coagulation cascade. Either of these pathways will result in decreased endothelial thromboresistance, leukocyte adhesion to damaged endothelium, complement consumption, enhanced vascular shear stress, and abnormal vWF fragmentation. The central and primary event in this progression is injury to the endothelial cells, which reduces the production of prostaglandin and prostacyclin, ultimately resulting in the loss of physiological thromboresistance, or high thrombus formation rate in blood vessels. Leukocyte adhesion to the damaged endothelial wall and abnormal von Willebrand factor (or vWF) release can also contribute to the increase in thrombus formation.[4] More ...
Some of which includes polycythemia vera. Since pruritus is a symptom of many serious diseases, it is important to rule out ...
In conditions such as neonatal polycythemia, a specific amount of the child's blood is removed and replaced with normal saline ... Partial exchange might be required for polycythemia. Nearly all exchange transfusions are allogeneic (that is, the new blood or ...
Polycythemia, the opposite of anemia Seidel, M. (2014). Autoimmune and other cytopenias in primary immunodeficiencies: ...
No evidence of polycythemia vera hematocrit < midpoint of normal range or normal red cell mass in presence of normal iron ... Vannucchi, AM (June 2010). "Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential ... Campbell PJ, Green AR (2005). "Management of polycythemia vera and essential thrombocythemia" (PDF). Hematology / the Education ... polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management". American ...
... including polycythaemia vera. In patients with polycythaemia, the reduction of mutant JAK2 concentrations by givinostat is ... "Treatment options for essential thrombocythemia and polycythemia vera". Expert Review of Hematology. 2 (1): 41-55. doi:10.1586/ ... Givinostat for the treatment of polycythaemia vera" (PDF). European Medicines Agency. WO patent application 1997/043251, " ... orphan drug designation in the European Union for the treatment of systemic juvenile idiopathic arthritis and polycythaemia ...
Moreover, they cause lymphocytopenia, eosinopenia, neutrophilia and polycythemia. In high doses, cortisol begins to act as a ...
Polycythaemia. *Congenital cyanosis (HbM Boston) arises from a mutation in the α-codon which results in a change of primary ...
Aerts has polycythemia, a fatal blood disease[clarification needed]. He is also the former owner and operator of the largest ... Aerts has a rare blood disease called polycythemia, which causes the body to produce excess red blood cells. Although the ...
"Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis". Experimental Hematology. 35 (11): 1657-1667 ...
In addition, these neuroendocrine tumors release erythropoietin (EPO) into circulating blood, and lead to polycythemia. ... leading to polycythemia, paragangliomas, and somatostatinomas". Blood. 121 (13): 2563-6. doi:10.1182/blood-2012-10-460972. PMC ... "Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia". The New England Journal of Medicine. 367 (10): ...
JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial ... "Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth". J Biol Chem. 282 (6): 3428-32. doi: ...
Laboratory findings in neonates may indicate polycythemia, leukopenia, or neutropenia. As they age, neurological deficits begin ...
December 1988). "[Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera]". Gan To Kagaku ... is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia and polycythemia vera. It ...
The cause of death was polycythemia, a kind of chronic leucosis. It is mentioned in a book Isaak Lipnitsky by Vadim Teplitsky ( ...
Passamonti, F.; Lazzarino, M. (2003). "Treatment of Polycythemia Vera and Essential Thrombocythemia: The Role of Pipobroman". ...
In 2014, it was approved in polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea ... 2015). "Ruxolitinib versus standard therapy for the treatment of polycythemia vera". N. Engl. J. Med. 372 (5): 426-35. doi: ... and for polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea. Ruxolitinib is a ...
When the hematocrit rises to 60 or 70%, which it often does in polycythemia, the blood viscosity can become as great as 10 ... Tefferi A (May 2003). "A contemporary approach to the diagnosis and management of polycythemia vera". Curr. Hematol. Rep. 2 (3 ...
It may also develop as a side-effect of treatment with some drugs that target hematological disorders, such as polycythemia ... Najean Y, Rain JD (1997). "Treatment of polycythemia vera: the use of hydroxyurea and piprobroman in 292 patients under the age ... Primary myelofibrosis can begin with a blood picture similar to that found in polycythemia vera or chronic myelogenous leukemia ... Myelofibrosis can be a late complication of other myeloproliferative disorders, such as polycythemia vera, and less commonly, ...
Patients with JAK2V617F-negative polycythemia vera are instead positive for another class of activating JAK2 mutations - the ... 2007). "JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis". N. Engl. J. Med. 356 (5): 459-68. doi: ... 2005). "Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation ... 2005). "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera". Nature. 434 (7037): 1144- ...
It is often misdiagnosed as polycythemia, polycythemia vera, hyperviscosity syndrome, or sepsis. Most SCLS patients report ...
February 26, 1998). "Expression of Bcl-x in erythroid precursors from patients with polycythemia vera". New England Journal of ... xL was suggested to play additional roles in regulating this process in erythrocytes which could lead to a role in polycythemia ...
Pahl HL (2003). "PRV-1 mRNA expression and other molecular markers in polycythemia rubra vera". Curr. Hematol. Rep. 2 (3): 231- ... 2003). "Fluorescence in situ hybridization analysis of the PRV-1 gene in polycythemia vera: implications for its role in ... 2002). "Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia". J. Clin. Oncol. 20 (20): 4249-54. ... which is overexpressed in polycythemia rubra vera". Blood. 95 (8): 2569-76. PMID 10753836. Lalezari P, Murphy GB, Allen FH Jr ( ...
Erythrapheresis in patients with polycythaemia secondary to hypoxic lung disease.. Br Med J (Clin Res Ed) 1983; 286 doi: https ... Erythrapheresis in patients with polycythaemia secondary to hypoxic lung disease. Br Med J (Clin Res Ed) 1983; 286 :511 ... Erythrapheresis was performed in 10 patients with polycythaemia secondary to hypoxic lung disease (mean PaO2, 6.8 kPa (51 mm Hg ... Erythrapheresis significantly improved symptoms, mental function, and work performance in patients with polycythaemia secondary ...
Since meat-type chickens can develop pulmonary hypertension from increased erythropoiesis and polycythaemia, two trials were ... Since meat-type chickens can develop pulmonary hypertension from increased erythropoiesis and polycythaemia, two trials were ...
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia Ang SO., Chen H., Hirota K., Gordeuk VR., Jelinek J ...
Primary polycythemia[edit]. Main article: Polycythemia vera. Primary polycythemias are due to factors intrinsic to red cell ... Polycythemia (also known as polycythaemia or polyglobulia) is a disease state in which the hematocrit (the volume percentage of ... Relative polycythemia[edit]. Relative polycythemia is an apparent rise of the erythrocyte level in the blood; however, the ... Secondary polycythemia[edit]. Secondary polycythemia is caused by either natural or artificial increases in the production of ...
... is a disorder of the bone marrow. It mainly causes too many red blood cells to be produced. The numbers of ... Polycythemia vera is a bone marrow disease that leads to an abnormal increase in the number of blood cells. The red blood cells ... Polycythemia vera is a disorder of the bone marrow. It mainly causes too many red blood cells to be produced. The numbers of ... Polycythemia vera is a bone marrow disease that leads to an abnormal increase in the number of blood cells. The red blood cells ...
Polycythemia vera is a condition characterized by an increased number of red blood cells in the bloodstream. Explore symptoms, ... Individuals with polycythemia vera have an increased risk of deep vein thrombosis. (DVT), a type of blood clot that occurs in ... Mutations in the JAK2 and TET2 genes are associated with polycythemia vera. Although it remains unclear exactly what initiates ... In rare instances, polycythemia vera has been found to run in families. In some of these families, the risk of developing ...
Find out more about the symptoms of polycythemia vera, how it affects your body, and what causes it. ... You can have polycythemia vera for years without knowing it. ... What Is Polycythemia Vera?. Polycythemia vera (PV) is a rare ... Doctors dont know what causes polycythemia vera. Its not linked to anything you do, the way smoking makes you more likely to ... National Heart, Lung, and Blood Institute: "Explore Polycythemia Vera.". Johns Hopkins Medicine, The Sidney Kimmel ...
Of 113 Patients with polycythemia vera (P. vera) who had been followed for the last 8 years, 30 cases (27%) developed myeloid ... Polycythemia vera Myeloid leukemia Histopathology Ultrastructure Cytogenetics Survival Supported by the Deutsche ... Masouredis SP, Lawrence JH (1957) The problem of leukemia in polycythemia vera. Am J Med Sci 233:268-274Google Scholar ... Wurster-Hill DH, McIntyre OR (1978) Chromosome studies in polycythemia vera. Virchows Arch B Cell Path 29:39-44Google Scholar ...
O Polycythemia vera é uma condição rara que afecte a medula, que é lenta progredir e se torna tipicamente em uma vida mais ... Que causa o Polycythemia Vera?. O Polycythemia vera torna-se na medula. As células estaminais na medula produzem os três tipos ... Sintomas do Polycythemia Vera. Os povos com polycythemia vera não podem apresentar nenhuns sintomas. Contudo, o baço pode ... Diagnóstico do Polycythemia Vera. Há um número de testes de diagnóstico disponíveis para confirmar casos do polycythemia vera. ...
Update - Polycythemia Vera Research in Pennsylvania-Schuylkill, Luzerne, and Carbon Counties (September 2012) Cdc-pdf. [PDF - ... Determination of accuracy of Polycythemia Vera diagnoses and use of the JAK2V617F test in the diagnostic scheme Cdc-pdf. [PDF ... Updated and expanded study of polycythemia vera and other myeloproliferative neoplasms in the tri-county area Cdc-pdf. [PDF - ... Fact sheet: Geographic study of polycythemia vera occurrence in central Pennsylvania (2001-2007) Cdc-pdf. [PDF - 105 KB] ...
Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera PharmaEssentia (Taipei, Taiwan) ... Jakafi receives expanded approval from FDA for use in treatment of polycythemia vera Diplomat Pharmacy, Inc., the nations ... Although those diseases, beta-thalassemia and polycythemia vera, have opposite effects on red blood cell production, treating ... mono-pegylated interferon for the first line treatment of polycythemia vera. ...
Polycythemia vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant, and neoplastic marrow disorder. ... encoded search term (Polycythemia Vera) and Polycythemia Vera What to Read Next on Medscape. Related Conditions and Diseases. * ... Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986 Apr. 23( ... The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American ...
I was diagnosed with Polycythemia Vera about 2 years ago. I went through 4 weeks of blood draws (a pint each time) and that ... I was diagnosed with Polycythemia Vera about 2 years ago. I went through 4 weeks of blood draws (a pint each time) and that ...
Polycythemia vera (PV) is a type of slow-growing blood cancer. If you have polycythemia vera, your body makes too many red ... Polycythemia vera (PV) is a type of slow-growing blood cancer. If you have polycythemia vera, your body makes too many red ... While there is no cure for PV, treatment can help you manage symptoms.[1] If you have polycythemia vera, talk to your doctor ... How to Treat Polycythemia Vera. Co-authored by Janice Litza, MD Updated: March 31, 2019 ...
Polycythemia vera (PV) is a benign, but chronic and progressive, form of blood cancer. The condition causes your blood to ... Polycythemia vera (PV) is a rare form of blood cancer. Theres no cure, but you can control PV through treatment. Learn about ... Polycythemia vera (PV) is a chronic and progressive form of blood cancer. Early diagnosis can help decrease the risk of life- ... Polycythemia vera (PC) may not be discovered until you visit your doctor for another reason. If your doctor suspects you have ...
Polycythemia vera occurs when the body produces too many red blood cells. The symptoms can be hard to detect, but here are some ... Polycythemia Vera. Polycythemia vera is a bone marrow disorder in which the body produces too many red blood cells. Heres what ... Polycythemia Vera: Doctor Discussion Guide. Since polycythemia vera is a type of blood cancer, youll want to see a ... Getting Tested for Polycythemia Vera. To diagnose polycythemia vera, your doctor will probably conduct several tests. Keep ...
Polycythemia vera (PV) develops when the body makes too many red blood cells and sometimes too many white blood cells or ... Polycythemia vera develops more often in men. Most people with polycythemia vera do not have a family history of this disease. ... Polycythemia vera (PV) is also called polycythemia rubra vera. It is a myeloproliferative neoplasm. It mainly causes the body ... Polycythemia vera may not cause any signs or symptoms in its early stages. Symptoms can develop when too many red blood cells ...
Polycythemia rubra vera, Polycythemia with chronic cyanosis, Primary polycythemia, Splenomegalic polycythemia, Vaquez disease ... Polycythemia Vera. Polycythemia vera (POL-e-si-THEE-me-ah VAY-rah or VE-rah), or PV, is a rare blood disease in which your body ... Also called: Cryptogenic polycythemia, Erythremia, Erythrocytosis, Myelopathic polycythemia, Myeloproliferative disorder, Osler ... Polycythemia Vera. A disease in which there are too many red blood cells in the bone marrow and blood, causing the blood to ...
... Vikram M. Raghunathan,1 James N. Butera,1,2 and Diana O. Treaba3 ... No other primary or secondary cause of his polycythemia was identified. This is the first described case of heterozygous ...
Definition of polycythemia rubra vera. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and ...
Polycythemia vera (PV) is a disorder of the multipotent hematopoietic stem cell that manifests as excess production of normal ... Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. Wasserman LR, Berk ... Two key aspects of polycythemia vera biology can identify it: clonality and erythropoietin (Epo) independence. In polycythemia ... The incidence of polycythemia vera is reported to be 4.9 cases per 100,000 population in Baltimore. A more recent review of ...
Twin anemia-polycythemia sequence, abbreviated as TAPS, is a form of chronic inter-twin transfusion. Different stages of TAPS ... "Twin Anemia-Polycythemia Sequence in Two Monochorionic Twin Pairs Without Oligo-Polyhydramnios Sequence". Placenta. 28 (1): 47- ... "Twin Anemia-Polycythemia Sequence: Diagnostic Criteria, Classification, Perinatal Management and Outcome". Fetal Diagnosis and ... "Fetoscopic laser treatment of twin-to-twin transfusion syndrome followed by severe twin anemia-polycythemia sequence with ...
... lower altitude place help polycythemia vera? I now live at 4,750ft. above sea level, cold dry climate. My doctor says no, it ... There are several types of polycythemia. Primary polycythemia, often called polycythemia vera (PCV), polycythemia rubra vera ( ... Polycythemia Support Group. Polycythemia is a condition in which there is a net increase in the total circulating erythrocyte ( ... Could moving to a warm, lower altitude place help polycythemia vera? I now live at 4,750ft. above sea level, cold dry climate. ...
Primary polycythemia is caused by a changes in the bodys JAK2 gene, but what causes this change is not known. Secondary ... polycythemia is caused by long-term exposure to low oxygen levels (for example, at high altitudes). Symptoms include fatigue, ... Polycythemia is a condition in which the bodys red blood cells are elevated. ... Polycythemia can be divided into two categories; primary and secondary.. *Primary polycythemia: In primary polycythemia the ...
The approach to the patient with polycythemia will be ... Polycythemia is a laboratory finding in which there is an ... Primary polycythemia - Primary polycythemia is caused by an acquired or inherited mutation leading to an abnormality within RBC ... Absolute polycythemia - In absolute polycythemia (also called erythrocytosis) there is an increased RCM. Patients are further ... Relative polycythemia. In: Polycythemia Vera and the Myeloproliferative Disorders, Wasserman LR, Berk PD, Berlin NI (Eds), WB ...
Polycythemia vera (adult). Mayo Clinic. 2019.. *Cuthbert D, et al. Polycythemia vera-associated complications: Pathogenesis, ... If you have polycythemia vera, blood tests might reveal:. *More red blood cells than normal and, sometimes, an increase in ... If you have polycythemia vera, analysis of your bone marrow or blood might show the gene mutation thats associated with the ... You can take steps to help yourself feel better if youve been diagnosed with polycythemia vera. Try to:. *Exercise. Moderate ...
... polycythemia • radiation releases on toxic Treasure Island • radiation sickness • radioactive and chemical contaminants • ...
... are more common than polycythemia vera and must be excluded. Diagnosis is made using criteria developed by the Polycythemia ... Polycythemia vera should be suspected in patients with elevated hemoglobin or hematocrit levels, splenomegaly, or portal venous ... Polycythemia vera is a chronic myeloproliferative disorder characterized by increased red blood cell mass. The resultant ... Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, ...
... polycythemia, Polycythemia vera -RETIRED-, Polycythemia Vera, Primary polycythaemia, polycythaemia rubra vera, polycythemia ... Polycythaemia rubra vera, [M]Polycythaemia vera, [M]Polycythemia rubra vera, [M]Polycythemia vera, polycythemia vera, ... Polycythemia Rubra, Polycythemia Rubra Veras, Polycythemia Rubra Vera, Veras, Polycythemia Rubra, erythraemia, polycythaemia ... polycythaemia rubra vera, vera; polycythaemia vera, polycythaemia vera, Erythremie, Polycythaemia vera, Vasquez-Osler-ziekte, ...
Maintaining patients with polycythemia vera at hematocrit levels below 45% reduced thrombotic complications without increasing ... Polycythemia Vera Better with Low Hematocrit. by John Gever, Senior Editor, MedPage Today December 8, 2012 ... In polycythemia vera, patients produce an excessive number of otherwise normal red blood cells, raising blood volume and ... "Women normally have a lower red-cell mass and hematocrit than men, and women with polycythemia vera are at risk for intra- ...
What is polycythaemia? And what are the symptoms of a raised red cell count? ... Polycythaemia (raised red cell count). What is polycythaemia? And what are the symptoms of a raised red cell count? ... What is polycythaemia?. Doctors use the terms polycythaemia and erythrocytosis if you have too many red blood cells. ... Less often it occurs due to an abnormality of the red cells in the bone marrow itself, otherwise known as polycythaemia rubra ...
... It is common for sufferers to feel very fatigued, and often there are headaches, light- ... A drug called hydroxyurea can help control polycythemia, and I have had a patient on this for many years, who used to feel as ... Im 43 and was diagnosed with polycythaemia a couple of years ago. ... and I am assuming that you have the condition whose full name is polycythaemia rubra vera, or PV. ...
  • JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera. (mysciencework.com)
  • To investigate the incidence and clinical significance of the JAK2 mutation, we performed allele-specific polymerase chain reaction (PCR) and enzyme-based assessment in 11 idiopathic erythrocytosis (IE) and 15 polycythemia vera (PV) patients. (mysciencework.com)
  • Hematological, Immunological and Biochemical Evaluation in Patients with Secondary Polycythemia. (iasj.net)
  • The aim of this study was to investigate whether the relationships between Hematological, Immunological, Biochemical parameters and heavy cigarette smoking in patients with secondary polycythemia, to reach such aim, the study included 60 individuals. (iasj.net)
  • Background: Secondary Polycythemia (SP) mean an elevated of erythrocytes numbers and hemoglobin above normal levels which as more than 18 g / liter in males or 16 g / liter in females, and the elevated red blood cell above the normal level lead to many complication as thromboembolisim, hypertension, and gout.Objectives: The study aims to assess find out the effectiveness of instructional program application on secondary polycythemic clients. (iasj.net)
  • In some of these families, the risk of developing polycythemia vera appears to have an autosomal dominant pattern of inheritance . (medlineplus.gov)
  • Autosomal dominant inheritance means that one copy of an altered gene in each cell is sufficient to increase the risk of developing polycythemia vera, although the cause of this condition in familial cases is unknown. (medlineplus.gov)
  • Mutations in the JAK2 and TET2 genes are associated with polycythemia vera. (medlineplus.gov)
  • The symptoms associated with polycythemia vera are entirely nonspecific and due to increased blood viscosity, hypercoagulability, inappropriate release of inflammatory cytokines, and organomegaly. (oncologynurseadvisor.com)
  • By ordering this test the physician directs the molecular pathology laboratory to perform testing reflexively for the mutations commonly associated with polycythemia vera. (uiowa.edu)
  • There are no CT scan findings associated with polycythemia vera. (wikidoc.org)
  • Polycythemia vera (PCV), polycythemia rubra vera (PRV), or erythremia, occurs when excess red blood cells are produced as a result of an abnormality of the bone marrow . (wikipedia.org)
  • Hoppin EC, Lewis JP (1975) Polycythemia vera rubra progressing to Ph'-positive chronic myelogenous leukemia. (springer.com)
  • Polycythemia vera (PV) is also called polycythemia rubra vera. (cancer.ca)
  • Primary polycythemia, often called polycythemia vera (PCV), polycythemia rubra vera (PRV), erythremia, or just PV, occurs when excess erythrocytes are produced as a result of a proliferative. (dailystrength.org)
  • Less often it occurs due to an abnormality of the red cells in the bone marrow itself, otherwise known as polycythaemia rubra vera (PV) . (netdoctor.co.uk)
  • I'm very sorry to hear that you have this distressing condition, and I am assuming that you have the condition whose full name is polycythaemia rubra vera , or PV. (netdoctor.co.uk)
  • Polycythemia Rubra Vera, also known as PRV , is the primary presentation of the disease polycythemia . (everything2.com)
  • The article provides a useful overview of diagnosis and therapy of polycythemia rubra vera, among others. (aerzteblatt.de)
  • Also called polycythemia vera or polycythemia rubra vera, primary absolute polycythemia is characterized by increased formation and growth (hyperplasia) of the bone marrow tissue that is responsible for producing red blood cells. (petwave.com)
  • The cause of so-called polycythemia rubra vera is at present not known. (annals.org)
  • The signs and symptoms of neurological involvement in polycythemia rubra vera occur with extreme frequency (Osler, 25 Christian, 8 Mendel, 22 Brockbank 4 ), and indeed "it appears that neurologic manifestations are among the commonest symptoms in polycythemia vera" (Sloan 30 ). (annals.org)
  • Two main conditions that belong to this category are polycythemia vera (PV or polycythemia rubra vera [PRV]) and primary familial and congenital polycythemia (PFCP). (emedicinehealth.com)
  • The polycythaemia of chronic hypoxaemia may be more precisely termed erythrocytosis as, in contrast to polycythaemia rubra vera, 2 it is the red blood cell mass alone that is increased. (bmj.com)
  • The risk of vascular occlusion in patients with primary polycythaemia rubra vera relates both to degree of erythrocytosis and to thrombocytosis, and treatment guidelines in this disease recommend venesection to maintain a haematocrit ⩽ 45. (bmj.com)
  • Secondary polycythemia is caused by either natural or artificial increases in the production of erythropoietin , hence an increased production of erythrocytes. (wikipedia.org)
  • In secondary polycythemia, 6 to 8 million and occasionally 9 million erythrocytes may occur per millimeter of blood. (wikipedia.org)
  • Secondary polycythemia resolves when the underlying cause is treated. (wikipedia.org)
  • Iatrogenic - Secondary polycythemia can be induced directly by phlebotomy (blood letting) to withdraw some blood, concentrate the erythrocytes, and return them to the body. (wikipedia.org)
  • Genetic - Heritable causes of secondary polycythemia also exist and are associated with abnormalities in hemoglobin oxygen release. (wikipedia.org)
  • Conditions where the secondary polycythemia is not as a result of physiologic adaptation and occurs irrespective of body needs include: Neoplasms - Renal-cell carcinoma or liver tumors, von Hippel-Lindau disease, and endocrine abnormalities including pheochromocytoma and adrenal adenoma with Cushing's syndrome. (wikipedia.org)
  • Erythrocytosis - Causes include secondary polycythemia (an increase in red blood cell [RBC] counts, typically due to chronic hypoxemia), familial erythrocythemia, and relative polycythemia (a benign condition in which RBC numbers are normal but plasma volume is contracted, due to dehydration or to reduced venous compliance). (medscape.com)
  • No other primary or secondary cause of his polycythemia was identified. (hindawi.com)
  • Polycythemia can be linked to secondary causes, such as, chronic hypoxia or tumors releasing erythropoietin . (medicinenet.com)
  • Treatment of secondary polycythemia is dependent on the underlying condition. (medicinenet.com)
  • Secondary polycythemia generally occurs as a response to other factors or underlying conditions that promote red blood cell production. (medicinenet.com)
  • Causes of polycythemia are primary or secondary. (medicinenet.com)
  • In secondary polycythemia, factors external to red blood cell production (for example, hypoxia, sleep apnea , certain tumors) result in polycythemia. (medicinenet.com)
  • Secondary causes of increased red blood cell mass (e.g., heavy smoking, chronic pulmonary disease, renal disease) are more common than polycythemia vera and must be excluded. (aafp.org)
  • 5 , 6 Once a secondary cause is ruled out ( Table 2 7 ), the diagnosis of PV is made using a combination of major and minor criteria defined by the Polycythemia Vera Study Group (PVSG). (aafp.org)
  • Secondary polycythemia , which is caused by factors that reduce the amount of oxygen reaching the body's tissues, such as smoking, high altitude or congenital heart disease. (childrenshospital.org)
  • The red blood cells in some patients with secondary polycythemia may carry an abnormal form of hemoglobin that does not release oxygen readily (high-affinity hemoglobin). (childrenshospital.org)
  • There are several forms of polycythemia-primary polycythemia, secondary polycythemia, and stress polycythemia. (stdavids.com)
  • Absolute polycythemia may be further classified as primary, secondary, or Chuvash polycythemia. (wisegeek.com)
  • Secondary polycythemia is caused by excess production of erythropoietin, the hormone that controls red blood cell production. (wisegeek.com)
  • Secondary polycythemia can be a complication of hypoxic disease, in which oxygen levels in the blood are low, or of genetic mutations or kidney or liver tumors. (wisegeek.com)
  • When associated with low oxygen levels caused by lung disease, secondary polycythemia symptoms include sleep apnea and chronic cough. (wisegeek.com)
  • Your child may also be tested for a genetic mutation in the janus kinase 2 (JAK2) gene that occurs in primary polycythemia, but not in secondary polycythemia. (baycare.org)
  • Absolute polycythemia can further be broken down into primary and secondary forms. (petwave.com)
  • Absolute polycythemia can be either primary or secondary. (petwave.com)
  • Secondary absolute polycythemia is caused by an increase in the production and release of erythropoietin (EPO) by the kidneys. (petwave.com)
  • Regardless of the cause, when hypoxia develops, secondary absolute polycythemia usually also occurs. (petwave.com)
  • Erythrapheresis in patients with polycythaemia secondary to hypoxic lung disease. (bmj.com)
  • Erythrapheresis significantly improved symptoms, mental function, and work performance in patients with polycythaemia secondary to hypoxic lung disease. (bmj.com)
  • Secondary polycythemia can occur in a variety of settings: living at high altitude, cardiac or pulmonary disease causing low oxygenation ( chronic obstructive pulmonary disease [COPD], sleep apnea , etc), erythropoietin-secreting tumors, drugs, and reduced plasma volume, among others. (visualdx.com)
  • Erythropoietin levels are very helpful in distinguishing primary and secondary polycythemia. (visualdx.com)
  • Secondary polycythemia is more prevalent than PV. (visualdx.com)
  • In secondary polycythemia, most of the symptoms are related to the underlying condition responsible for polycythemia. (emedicinehealth.com)
  • Contrary to primary polycythemia in which overproduction of red blood cell results from increased sensitivity or responsiveness to Epo (often with lower than normal levels of Epo), in secondary polycythemia, more red cells are produced because of high levels of circulating Epo. (emedicinehealth.com)
  • Our differential diagnosis included primary and secondary polycythemia. (healio.com)
  • We sought a tentative diagnosis of secondary polycythemia, possibly caused by uterine fibroids. (healio.com)
  • Secondary polycythemia can be caused by a variety of erythropoietin-producing renal lesions and cancers. (healio.com)
  • Renal cysts, hydronephrosis, renal cell carcinoma, hepatocellular cancers and uterine myomas are known to cause increased erythropoietin secretion, thereby causing secondary polycythemia. (healio.com)
  • Androgen use is another common cause of secondary polycythemia. (healio.com)
  • Secondary polycythemia affects some people as a result of limited oxygen due to smoking or living at high altitudes. (pharmasave.com)
  • Although the cause of polycythemia vera is unknown, a number of factors are involved that appear to lead to secondary polycythemia. (pharmasave.com)
  • Most people who live at high altitudes don't appear to suffer secondary polycythemia. (pharmasave.com)
  • Secondary polycythemia is due to an increase in RBC counts following an increase in the hormone erythropoietin. (ndtv.com)
  • Adults with polycythaemia secondary to cyanotic congenital heart disease may be at greater risk from injudicious venesection than from their polycythaemia. (bmj.com)
  • This secondary polycythaemia, or erythrocytosis, is a physiological response to tissue hypoxia. (bmj.com)
  • Cario H, Goerttler PS, Steimle C, Levine RL and Pahl HL (2005) The JAK2 V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. (els.net)
  • [2] Polycythemia is sometimes called erythrocytosis , but the terms are not synonymous, because polycythemia refers to any increase in red blood cells, whereas erythrocytosis only refers to a documented increase of red cell mass. (wikipedia.org)
  • The state of chronically reduced plasma volume with elevated HGB or HCT has been called Gaisbock's disease, spurious polycythemia, stress erythrocytosis, apparent polycythemia, and pseudopolycythemia [ 1-4 ], although many may be examples of smokers' polycythemia (see 'Reduced plasma volume' below) [ 5 ]. (uptodate.com)
  • Absolute polycythemia - In absolute polycythemia (also called erythrocytosis) there is an increased RCM. (uptodate.com)
  • Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by an increased red blood cell mass (RCM), or erythrocytosis, which leads to hyperviscosity and an increased risk of thrombosis. (aafp.org)
  • Doctors use the terms polycythaemia and erythrocytosis if you have too many red blood cells. (netdoctor.co.uk)
  • Polycythemia (Erythrocytosis) Associated with Uterine Fibroids: A Case Report with Erythropoietic Activity Demonstrated in the Tumor. (annals.org)
  • Any cause of absolute erythrocytosis can mimic polycythemia. (oncologynurseadvisor.com)
  • Furthermore, in addition to presenting with isolated thrombocytosis, polycythemia vera can present with erythrocytosis alone, erythrocytosis and splenomegaly, erythrocytosis and leukocytosis or thrombocytosis, or all three together. (oncologynurseadvisor.com)
  • Finally, in polycythemia vera, in contrast to the other forms of erythrocytosis listed above, there is often expansion of the plasma volume as red cell production increases. (oncologynurseadvisor.com)
  • Thus, a normal hematocrit or hemoglobin level does not exclude the presence of absolute erythrocytosis when polycythemia vera is a diagnostic consideration. (oncologynurseadvisor.com)
  • Polycythemia vera (PV) is a rare chronic myeloproliferative disorder in which the bone marrow is characterized by clonal myeloproliferation causing erythrocytosis, increased red blood cell mass, and elevated hemoglobin and hematocrit. (visualdx.com)
  • The presence of an elevated red cell count is called erythrocytosis or a polycythaemia. (ndtv.com)
  • It can be raised due to many reasons and these causes may be subdivided into whether there is a 'true' or absolute erythrocytosis (polycythemia) due to an increase in red cells or an 'apparent' erythrocytosis when the red cells are not increased but are instead more concentrated. (ndtv.com)
  • Other complications of polycythemia vera include an enlarged spleen (splenomegaly), stomach ulcers, gout (a form of arthritis caused by a buildup of uric acid in the joints), heart disease, and cancer of blood-forming cells (leukemia). (medlineplus.gov)
  • If you have polycythemia vera, your body makes too many red blood cells which can cause complications like blood clots, which can cause stroke and heart attack. (wikihow.com)
  • The goal of treatments for polycythemia vera is to control symptoms and lower the risk of complications. (cancer.ca)
  • What are the possible complications of polycythemia vera in a child? (ahealthyme.com)
  • Complications depend on how severe the polycythemia is. (ahealthyme.com)
  • Arterial or venous thrombosis, considered the most serious complications of polycythemia vera, can occur, resulting in a heart attack, stroke, or pulmonary embolism. (nyhq.org)
  • Polycythemia vera can lead to serious complications if inadequately controlled, and these data demonstrate the ability of Jakavi to provide a durable and comprehensive clinical benefit in this patient population," said lead study investigator Jean-Jacques Kiladjian, MD, PhD, Hôpital Saint-Louis et Université Paris Diderot. (novartis.com)
  • Treatment can help in controling Polycythemia Vera the disease and its complications. (onlymyhealth.com)
  • Polycythemia (also known as polycythaemia or polyglobulia ) is a disease state in which the hematocrit (the volume percentage of red blood cells in the blood ) is elevated. (wikipedia.org)
  • People with polycythemia have an increase in hematocrit , hemoglobin , or red blood cell count above the normal limits. (medicinenet.com)
  • Polycythemia is normally reported in terms of increased hematocrit (hematocrit is the ratio of the volume of red blood cells to the total volume of blood) or hemoglobin concentration (hemoglobin is a protein responsible for transporting oxygen in the blood). (medicinenet.com)
  • Polycythemia is considered when the hematocrit is greater than 48% in women and 52% in men. (medicinenet.com)
  • Polycythemia vera, the hematocrit, and blood-volume physiology. (nih.gov)
  • Laboratory tests show a high hematocrit (red blood cell count) when polycythemia is present. (baycare.org)
  • Discussions of polycythemia in the literature are based on blood samples in which the hematocrit is based on a spun or centrifuged sample. (oncologynurseadvisor.com)
  • A hematocrit reading higher than 54% in a man or 49% in a woman may indicate polycythemia, but the diagnosis can not be made on the basis of this alone. (digitalnaturopath.com)
  • This reduces oxygen delivery to the kidneys, causing increased erythropoietin production and a resultant polycythemia. (wikipedia.org)
  • Two key aspects of polycythemia vera biology can identify it: clonality and erythropoietin (Epo) independence. (medscape.com)
  • Erythropoietin independence is the ability of erythroid colonies formed from the polycythemia vera hematopoietic stem cell to grow without erythropoietin. (medscape.com)
  • it includes polycythemia vera (PV) and rare familial variants (eg, activating mutations of the erythropoietin receptor, Chuvash polycythemia). (uptodate.com)
  • True polycythemia may be primary and is then called polycythemia vera (PV), a myeloproliferative disorder in which the RBC count increases without being stimulated by the red blood cell stimulating hormone erythropoietin. (ndtv.com)
  • Many of the signs and symptoms of polycythemia vera are related to a shortage of oxygen in body tissues. (medlineplus.gov)
  • this is referred to as relative polycythemia. (uptodate.com)
  • Relative polycythemia. (uptodate.com)
  • It may be due to excess red blood cells, in which case it is known as absolute polycythemia, or to a decreased blood plasma volume, a condition called relative polycythemia. (wisegeek.com)
  • Relative polycythemia is often caused by a loss of bodily fluids through dehydration, burns, or stress. (wisegeek.com)
  • A common symptom of relative polycythemia is high blood pressure, and symptoms similar to those of polycythemia vera may also be present. (wisegeek.com)
  • Relative polycythemia , sometimes called spurious polycythemia, refers to an apparent, but not actual, increase in the number of circulating red blood cells. (petwave.com)
  • For example, vomiting and diarrhea cause dehydration by depleting the overall amount of circulating fluid in the body, without reducing the number of circulating red blood cells, resulting in relative polycythemia. (petwave.com)
  • Transient polycythemia is a type of relative polycythemia that is caused by splenic contraction. (petwave.com)
  • Relative polycythemia can be prevented by ensuring that a dog is well-hydrated. (petwave.com)
  • The emergency treatment of polycythemia (e.g., in hyperviscosity or thrombosis) is by phlebotomy (removal of blood from the circulation). (wikipedia.org)
  • Findings on CT scan suggestive of polycythemia vera include enlarged lymph nodes, splenomegaly , and splanchnic venous thrombosis and pulmonary embolism . (wikidoc.org)
  • Ultrasound of the extremities can assist with diagnosis of deep vein thrombosis , which is commonly associated with high-risk polycythemia vera. (wikidoc.org)
  • The data provides new insights into the genetic abnormalities of polycythemia vera, establish a molecular basis for disease heterogeneity, and identify genes and pathways that may have value for targeted therapy outside the canonical JAK2 signaling pathway, as well as previously unrecognized genes potentially involved in promoting myelofibrosis, inflammation and thrombosis," Spivak and colleagues concluded. (healio.com)
  • Polycythemia vera (PV) is a rather benign myeloproliferative neoplasm, with near-normal life expectancy and increased risk for thrombosis related to too many blood cells and inflammation, all subsequent to hyperactive JAK-STAT intracellular pathway due to mutations in JAK2 tyrosine kinase. (healio.com)
  • Cytostatics such as busulfan and hydroxyurea are sometimes used for long-term management of polycythemia. (wikipedia.org)
  • Polycythemia is treated by phlebotomy (controlled blood letting) and hydroxyurea . (medicinenet.com)
  • Moreover, the even humbler treatment method of phlebotomy appears to be the therapy of choice for polycythemia vera, Spivak suggested, insofar as the study results indicated that hydroxyurea and aspirin did not make a difference in outcomes. (medpagetoday.com)
  • A drug called hydroxyurea can help control polycythemia, and I have had a patient on this for many years, who used to feel as you do, but now leads an active life and no longer needs phlebotomy. (netdoctor.co.uk)
  • Has had a diagnosis of hydroxyurea resistant or intolerant polycythemia vera (PV) or essential thrombocythemia (ET). (knowcancer.com)
  • Twin anemia-polycythemia sequence, abbreviated as TAPS, is a form of chronic inter-twin transfusion. (wikipedia.org)
  • Polycythemia vera (PV) is a chronic and progressive form of blood cancer. (healthline.com)
  • Polycythemia vera is a chronic myeloproliferative disorder characterized by increased red blood cell mass. (aafp.org)
  • Polycythemia vera is a chronic myeloproliferative disorder marked by an increase in red blood cells, according to the University of Chicago Medicine. (reference.com)
  • The prevalence of High Altitude Polycythemia (or Chronic Mountain Sickness) is between 8 and 15% in the high altitude regions of South America. (clinicaltrials.gov)
  • Thus, polycythemia vera must be considered as a great imitator, and since it is the most common of the three chronic myeloproliferative disorders, it should be the first disease considered when a chronic myeloproliferative disorder is a diagnostic consideration. (oncologynurseadvisor.com)
  • While polycythemia vera is considered a chronic condition without a cure, many treatments are available that help regulate the condition. (earthclinic.com)
  • Polycythemia vera (PV) is a chronic myeloproliferative disorder associated with cardiovascular events. (medsci.org)
  • Chronic carbon monoxide exposure can also lead to polycythemia. (emedicinehealth.com)
  • Polycythemia vera is a chronic, incurable blood cancer associated with an overproduction of blood cells. (marketwatch.com)
  • A patient with concomitant chronic lymphocytic leukemia (CLL) and polycythemia vera (PV) requiring therapeutic phlebotomy donated a large amount of phlebotomized blood to test this possibility. (springer.com)
  • To test such an approach, we used plasma from a patient (CLL831) with concomitant B-cell chronic lymphocytic leukemia (CLL) and polycythemia vera (PV), who donated blood made available from periodic phlebotomy for PV. (springer.com)
  • Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by clonal proliferation of hematopoietic progenitors resulting in expansion of the erythrocyte mass, and its clinical course is affected by cardiovascular events, the main cause of morbidity and mortality. (clinicaltrials.gov)
  • The approach to confirming a diagnosis of polycythemia vera is discussed separately. (uptodate.com)
  • See 'Clinical manifestations and diagnosis of polycythemia vera' . (uptodate.com)
  • Am now dealing with a diagnosis of polycythemia vera. (earthclinic.com)
  • Abdominal and chest CT scan may be helpful in the diagnosis of polycythemia vera. (wikidoc.org)
  • Has had a diagnosis of polycythemia vera and essential thrombocythemia according to the revised WHO 2008 criteria. (knowcancer.com)
  • What is the diagnosis of Polycythemia Vera? (onlymyhealth.com)
  • Diagnosis of polycythemia is by arterial or venous (not capillary) Hct. (merckmanuals.com)
  • Some people with polycythemia vera experience headaches, dizziness, ringing in the ears (tinnitus), impaired vision, or itchy skin. (medlineplus.gov)
  • Although mutations in the TET2 gene have been found in approximately 16 percent of people with polycythemia vera, it is unclear what role these mutations play in the development of the condition. (medlineplus.gov)
  • Doctors don't know why the body makes too many blood cells, but most people with polycythemia vera have a change, or mutation, in the JAK2 (Janus kinase 2) gene. (cancer.ca)
  • Most people with polycythemia vera do not have a family history of this disease. (cancer.ca)
  • People with polycythemia vera may be treated with different drugs. (cancer.ca)
  • Phlebotomy is usually the first treatment for people with polycythemia vera. (cancer.ca)
  • People with polycythemia vera are likely to live a normal lifespan with the proper treatments and precautions, according to the MPN Research Foundation. (reference.com)
  • With proper treatment, the average survival of people with polycythemia vera is 7 to 15 years. (pharmasave.com)
  • JAK2 gene mutations seem to be particularly important for the development of polycythemia vera, as nearly all affected individuals have a mutation in this gene. (medlineplus.gov)
  • [ 3 ] Rather, an as-of-yet unidentified mutation or mutations predispose to the acquisition of polycythemia vera. (medscape.com)
  • Is it true polycythemia vera in absence of mutations? (onclive.com)
  • Mutations of the Janus kinase 2 ( JAK2 ) gene are responsible in a high proportion of cases of polycythemia vera. (merckmanuals.com)
  • Janus kinase 2 ( JAK2 ) mutations define polycythemia vera (PV). (bloodjournal.org)
  • The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. (medscape.com)
  • ReportsWorldwide has announced the addition of a new report title Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2017 to its growing collection of premium market research reports. (openpr.com)
  • Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2017, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape. (openpr.com)
  • Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H2 2017, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape. (mynewsdesk.com)
  • Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. (mynewsdesk.com)
  • Absolute polycythemia is an actual increase in the number of circulating red blood cells. (petwave.com)
  • The cause of primary absolute polycythemia is not known. (petwave.com)
  • A superproduçao destes tipos de glóbulos pode conduzir a outras circunstâncias similares ao polycythemia vera, tal como o thrombocythemia ou (ET) o myelofibrosis essencial. (news-medical.net)
  • Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (medscape.com)
  • Polycythemia vera may develop into acute myelogenous leukemia (AML) or idiopathic myelofibrosis. (cancer.ca)
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. (openpr.com)
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology). (openpr.com)
  • The pipeline guide reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. (openpr.com)
  • The pipeline guide reviews key companies involved in Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics and enlists all their major and minor projects. (openpr.com)
  • The pipeline guide evaluates Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. (openpr.com)
  • Find and recognize significant and varied types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology). (openpr.com)
  • Formulate corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline depth and focus of Indication therapeutics. (openpr.com)
  • For example, isolated thrombocytosis, associated with a JAK2 mutation, can be the presenting manifestation of essential thrombocytosis, primary myelofibrosis, or polycythemia vera, while both essential thrombocytosis and primary myelofibrosis can evolve into polycythemia vera, and polycythemia vera can evolve to a myelofibrosis state. (oncologynurseadvisor.com)
  • The World Health Organization (WHO) classification system recognizes four variants of myelofibrosis (MF): primary (PMF), prefibrotic (pre-PMF), post-essential thrombocythemia (post-ET MF) and post-polycythemia vera (post-PV MF). (nature.com)
  • Dr. Mesa answered your questions about polycythemia vera, essential thrombocythemia and myelofibrosis in the MPN Community on CancerConnect. (cancerconnect.com)
  • The most common JAK2‐activating mutation, V617F, is responsible for the clinical phenotype of polycythaemia vera and that of approximately 50% of cases of essential thrombocytosis and primary myelofibrosis. (els.net)
  • Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. (marketresearch.com)
  • Ruxolitinib (trade name: Jakavi) has been approved since March 2015 for the treatment of polycythemia vera in adults. (nih.gov)
  • Ruxolitinib (trade name: Jakavi) has been approved since March 2015 for the treatment of adults with polycythaemia vera, a rare disease of the bone marrow. (eurekalert.org)
  • The recommended starting dose of ruxolitinib in polycythemia vera is 10 mg twice daily. (ascopost.com)
  • Primary familial polycythemia, also known as primary familial and congenital polycythemia (PFCP), exists as a benign hereditary condition, in contrast with the myeloproliferative changes associated with acquired PCV. (wikipedia.org)
  • The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. (mynewsdesk.com)
  • Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. (mynewsdesk.com)
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycythemia Vera (Oncology). (mynewsdesk.com)
  • The pipeline guide reviews pipeline therapeutics for Polycythemia Vera (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. (mynewsdesk.com)
  • The pipeline guide evaluates Polycythemia Vera (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. (mynewsdesk.com)
  • Find and recognize significant and varied types of therapeutics under development for Polycythemia Vera (Oncology). (mynewsdesk.com)
  • Polycythemia vera is a bone marrow disease that leads to an abnormal increase in the number of blood cells. (ebi.ac.uk)
  • Polycythemia vera is a disorder of the bone marrow. (ebi.ac.uk)
  • Ellis JT, Peterson P (1979) The bone marrow in polycythemia vera. (springer.com)
  • Polycythemia vera is a bone marrow disorder in which the body produces too many red blood cells. (healthline.com)
  • Polycythemia vera is due to abnormally increased red cell production in the bone marrow. (medicinenet.com)
  • If your doctor suspects that you have polycythemia vera, he or she might recommend collecting a sample of your bone marrow through a bone marrow aspiration or biopsy. (mayoclinic.org)
  • If you have polycythemia vera, analysis of your bone marrow or blood might show the gene mutation that's associated with the disease. (mayoclinic.org)
  • Primary polycythemia , caused by overproduction of red blood cells by the bone marrow due to mutation or biological factor in the body. (childrenshospital.org)
  • Polycythemia vera, a bone marrow disorder causing abnormal increase in the number of blood cells, is related to a gene defect called JAK2V617F, according t. (reference.com)
  • Polycythemia vera occurs when a bone marrow cell mutation interferes with the production of blood cells. (reference.com)
  • Polycythemia is a condition that occurs when the bone marrow produces an abnormal and excessive amount of red blood cells and platelets in the blood. (stdavids.com)
  • In primary polycythemia, also called polycythemia vera, the bone marrow overproduces red blood cells. (wisegeek.com)
  • Polycythemia vera is a blood cancer that progresses slowly and features the overproduction of red blood cells by the bone marrow. (reference.com)
  • With polycythemia vera, the bone marrow makes too many red blood cells. (ahealthyme.com)
  • This can occur either as a primary condition in which the bone marrow produces too many red blood cells (called polycythemia vera) or it may occur as a reaction to other diseases and conditions (such as hypoxia or low oxygen levels due to any reason) that drive the body to produce an increased number of red blood cells. (emedicinehealth.com)
  • Polycythemia vera (PV) is related to a genetic mutation in the JAK2 gene, which is thought to increase the sensitivity of bone marrow cells to Epo, resulting in increased red blood cell production. (emedicinehealth.com)
  • Polycythemia vera (also called primary polycythemia ) is a rare growth disorder of the bone marrow, occurring when the marrow is overactive and produces more blood cells than the body needs. (pharmasave.com)
  • Polycythemia vera stems from problems with the bone marrow. (pharmasave.com)
  • Polycythemia vera (PV) is a myeloproliferative disease characterized by an increased red-cell mass and usually an increase in megakaryocytes in the bone marrow and platelets in the peripheral blood. (bloodjournal.org)
  • Polycythemia vera (PV) is a cloned erythrocytotic disease manifested by high proliferation and apoptosis in the bone marrow. (bioportfolio.com)
  • The symptoms of primary polycythemia occur gradually and vary from person to person. (stdavids.com)
  • Polycythemia may occur with many different conditions. (baycare.org)
  • Seizures can also occur with polycythemia. (baycare.org)
  • Polycythemia can occur when there are too many red blood cells in an infant's blood. (stlukes-stl.com)
  • The JAK2V617F mutation leads to constitutive phosphorylation, thus constitutive activity and STAT recruitment, which provides the proliferative advantage seen in polycythemia vera. (medscape.com)
  • A mouse model of this mutation produced a clinical phenotype consistent with polycythemia vera. (medscape.com)
  • Polycythemia vera is caused by a mutation in the JAK2V617F gene, notes Healthline. (reference.com)
  • Nearly all cases of primary polycythemia are believed to be caused by a mutation in the janus kinase 2 gene (JAK2). (stdavids.com)
  • Because polycythemia vera and its companion myeloproliferative disorders can share in common the same mutation, their clinical features overlap, and because the clinical manifestations of these disorders evolve over time, it is often not possible to distinguish between them on clinical grounds. (oncologynurseadvisor.com)
  • once a mutation is identified no further analysis is performed (See the Polycythemia vera Algorithm ). (uiowa.edu)
  • Polycythemia vera (PV) is a clonal myeloproliferative disorder (MPD) caused by somatic mutation(s) arising in a hematopoietic multipotent cell. (haematologica.org)
  • Although the exact cause of polycythemia vera is unknown, researchers have found that a specific gene mutation is associated with almost all people with this condition. (pharmasave.com)
  • Polycythemia vera is caused by clonal hematopoiesis due to a mutation in an hematopoietic stem cell. (merckmanuals.com)
  • JAK2 V617F‐activating mutation is the most frequent genetic alteration in polycythaemia vera, essential thrombocytosis and primary meylofibrosis. (els.net)
  • Are you sure your patient has neonatal polycythemia? (oncologynurseadvisor.com)
  • Prolonged poor oxygen delivery to the fetus (intrauterine hypoxia) due to insufficiency of the placenta can also lead to neonatal polycythemia. (emedicinehealth.com)
  • Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L (1976) Polycythemia vera: stem cell and probable clonal origin of the disease. (springer.com)
  • In polycythemia vera, a single clonal population of erythrocytes, granulocytes, platelets, and variable clonal B cells arises when a hematopoietic stem cell gains a proliferative advantage over other stem cells. (medscape.com)
  • Genome-wide scanning that compared clonal polycythemia vera and nonclonal cells from the same individuals revealed a loss of heterozygosity (LOH) in chromosome 9p. (medscape.com)
  • Polycythemia vera (PV) is a disorder of the multipotent hematopoietic stem cell that manifests as excess production of normal erythrocytes and variable overproduction of leukocytes and platelets. (medscape.com)
  • Results We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143 , miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b , miR-30c and miR-150 in polycythemia vera reticulocytes. (haematologica.org)
  • Polycythemia vera involves increased production of all cell lines, including RBCs, WBCs, and platelets. (merckmanuals.com)
  • The terms polycythemia and hyperviscosity are often used interchangeably but are not equivalent. (merckmanuals.com)
  • Polycythemia is significant only because it increases risk of hyperviscosity syndrome. (merckmanuals.com)
  • Incidence of polycythemia is about 3 to 4% (range 0.4 to 12%), and about half of infants with polycythemia have hyperviscosity. (merckmanuals.com)
  • Polycythemia vera is one type of myeloproliferative disorder (MPD). (nyhq.org)
  • In these families, people seem to inherit an increased risk of polycythemia vera, not the disease itself. (medlineplus.gov)
  • The risk of polycythemia vera increases with age. (mynewsdesk.com)
  • Polycythemia vera typically develops in adulthood, around age 60, although in rare cases it occurs in children and young adults. (medlineplus.gov)
  • This process occurs in the absence of Epo and explains both the Epo independence and Epo hypersensitivity of polycythemia vera colonies. (medscape.com)
  • The following are common symptoms associated with polycythemia and other diseases that should be considered in the differential diagnosis before attributing the symptom to polycythemia. (oncologynurseadvisor.com)
  • Listed below are some combinations of symptoms associated with Polycythemia in pregnancy, as listed in our database. (rightdiagnosis.com)
  • Hyperuricemia, hypertension, and proteinuria associated with high-altitude polycythemia. (biomedsearch.com)
  • We examined the relationship between high-altitude polycythemia and proteinuria and hyperuricemia in Cerro de Pasco, Peru (altitude, 4,300 m). (biomedsearch.com)
  • To diagnose polycythemia vera, your doctor will probably conduct several tests. (healthline.com)
  • Some of the same tests used to rule out or diagnose leukemia are also used to diagnose polycythemia vera. (cancer.ca)
  • Because microRNA regulate hematopoietic differentiation, we hypothesized that dysregulated expression of microRNA may contribute to the pathophysiology of polycythemia vera. (haematologica.org)
  • Living for long periods at high altitudes where there's less oxygen may lead to polycythemia. (pharmasave.com)
  • Vannucchi AM. From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. (medscape.com)